Tag: Biologics Development

Background: The client was advancing a Phase II biologic in a chronic inflammatory disease category already dense with competition. While early clinical data showed encouraging efficacy and a manageable safety profile, the team faced a familiar challenge: how to stand out in a market where... Continue reading